The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascentage Pharma Group International Unsponsored ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...

VertexOne, a leading provider of cloud software designed to revolutionize the customer experience within the energy and utility industry, announced today the appointment of Andrew Osler to its Board ...

Mar 26, 2025 The McGee group is one of the two smallest groups with an outer automorphism that preserves conjugacy classes. My route to understanding this fact was a long and winding one.

EasyPark Group, a leading provider of digital parking and mobility solutions, and Google Cloud today announced a strategic collaboration to support its multicloud strategy and advance its AI journey.

Nonprofit organizations utilizing the latest ezCheckprinting and virtual printer software no longer need be concerned about ...

Vertex Pharmaceuticals continues to see patients with sickle ... are no longer cost prohibitive," Marks said earlier this ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...